In anticoagulation treatment with warfarin, the risk of thrombo-embolic events must be weighed against the risk of bleeding. Time in therapeutic range (TTR) is an important tool to assess the quality of anticoagulation treatment, and has been shown to correlate with less bleeding and thrombo-embolic complications. AuriculA, the Swedish national quality registry for atrial fibrillation and anticoagulation, is used for follow-up and dosage control of warfarin. This is the first report of TTR in AuriculA and, in a subgroup of two centres, bleeding and thrombo-embolic complications during 2008.
Introduction
Approximately 150 000 patients in Sweden are treated with warfarin, corresponding to 1.5% of the population. 1 Atrial fibrillation is the most common and rapidly growing treatment indication, and in this population, warfarin treatment has been shown to reduce the risk for embolic stroke by two-thirds. 2 At the same time, warfarin treatment confers a substantial risk of bleeding, and the reduction in thrombo-embolic events must be carefully weighed against the risk of bleeding for each individual patient. This benefit to risk ratio is often not known for the individual patient due to too few and small studies, or limitations in patient selection where the elderly patients with multiple diagnoses do not fit in. 3 Monitoring and tight control of anticoagulation treatment reduce the risk of both thrombosis and bleeding, 4 -6 and time in therapeutic range (TTR) 7 is an important tool to assess the quality of the anticoagulation treatment given. In the USA, anticoagulation clinics have been associated with higher TTR compared with standard community care 5 where as in Sweden, a study comparing anticoagulation clinics with standard community care has not shown any differences in complications, indicating a potential difference between countries. 8 However, this study did not validate TTR against the frequency of complications. The recently published multicentre RELY trial, 9 comparing anticoagulation treatment with warfarin with two different doses of the thrombin inhibitor dabigatran in patients with atrial fibrillation, reported a TTR of 64%, which is in line with previous randomized controlled trials. 4 Compared with warfarin, a significant decrease in thrombo-embolic events was seen with the higher 150 mg b.i.d. dose, and bleeding complications were lower with the 110 mg b.i.d. dose, favouring dabigatran treatment. In Sweden, the TTR of warfarin treatment was very high (77%), and retrospective subgroup analysis showed that when centres were separated according to TTR, a high TTR (.72.4%) correlated to a reduced risk of both thrombo-embolic complications and major bleeding.
10
The Swedish national quality registry for atrial fibrillation and anticoagulation (AuriculA) was founded in 2006. The registry, used for patient characteristics, follow-up, and dosage control of warfarin in patients with different indications of anticoagulation treatment, is growing rapidly and has by 31 December 2008 over 16 000 patients and more than 225 000 international normalised ratio (INR) values registered. In this paper, we report patient characteristics and TTR for the participating centres and, in a subgroup of two centres, bleeding and thrombo-embolic complications during the year 2008.
Methods
AuriculA is a Swedish national quality registry of patients with atrial fibrillation. The registry includes key patient characteristics, information on treatment, concurrent illnesses, investigations, and complications to atrial fibrillation as quality indicators. AuriculA, created in 2006 with the intent to improve anticoagulation treatment and to evaluate the benefits of modifications, also has a separate part for dosing of anticoagulation treatment regardless of indication (www. ucr.uu.se/auricula). The web-based dosing program suggests the dosage of warfarin according to an algorithm based on the last two INR results. Key outcome measures for patients on anticoagulation treatment are major bleeding according to ISTH (International Society on Thrombosis and Haemostasis) definitions 11, 12 and clinically verified arterial or venous thrombosis. AuriculA complies with the Declaration of Helsinki and the Ethics Committee at Uppsala University has approved research using this registry. Data on age, sex, treatment indications, and TTR were extracted from AuriculA for patients listed during the period 1 January 2008 -31 December 2008. In a subgroup analysis of two centres, the hospitals in Malmö and Sundsvall, we performed a follow-up of all patients registered in 2008 regardless of indication of anticoagulation treatment. In these two centres, we aimed to assess and verify the frequency of major bleedings, arterial and venous thrombo-embolism and relate data to the mean TTR in each patient category. Data on complications are collected prospectively in AuriculA through routine follow-up telephone calls, but to assure that no complications were missed, we reviewed the hospital records of every patient treated with warfarin in these two centres. All 18 391 patients in In a subgroup of two centres, data on 4273 patients on anticoagulation treatment with warfarin were extracted from AuriculA and complications to warfarin treatment (major bleeding and thrombo-embolic events) were verified against hospital records. Age in these patients was defined as the age of the patient at the time of the event. If a patient had more than one event, only the first in each separate category was used for statistical analysis. The TTR for every patient in the subgroup during 2008 was extracted from AuriculA and complications were converted to rates (per cent per patient-year) and reported with appropriate 95% CI for a rate. The mean TTR, of the separate indications of anticoagulation treatment in the subgroup, was based on the mean of the TTR of patients with that indication. Three thousand six hundred and nineteen patients on anticoagulation treatment with warfarin .1 week and target INR 2.0 -3.0 were included in the analysis of TTR for the different indications in the subgroup. As a result, 611 patients with other target INR levels, and 43 patients without enough INR results to calculate TTR, were excluded. Complications were tested for differences in patient characteristics. Differences in age were tested using Wilcoxon's test and differences in gender and treatment indications were tested using Pearson's test. In patients with complications, only INR values before the event was used for statistical analysis. All statistical tests were two-sided and the P-value threshold for significance was ,0.05. For statistical analyses, R version 2.10.1 (R Foundation for Statistical Computing, Vienna, Austria) and SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) were used. The main indications of treatment with warfarin were atrial fibrillation (64%), venous thrombosis (19%), and heart valve dysfunction (13%) ( Table 1 ). The mean age (SD) of the whole population of 18 391 patients was 70 (12) years. The mean age (SD) was higher in women, 73 (12) , than in men, 69 (12) . In patients with a target INR of 2 after exclusion of the first week of therapy, the adjusted mean TTR (n ¼ 15 601) was 76.2% ( Figure 2) . A TTR of .70% was consistent in all age groups, and a significant correlation between TTR and increasing age (P , 0.001) was seen ( Figure 3) . The mean weekly dose of warfarin decreased with increasing age, from 43 mg/week in patients of age 41 -50, to 24 mg/week in patients of age 81 -90 (Figure 4 , P , 0.001). In the subgroup of two centres (n ¼ 4273), the mean TTR was 74.9%, and a total of 87 bleedings and 58 thrombo-embolic events was detected during a total of 3377 treatment years ( Table 2 ). There were 14 CNS (16%), 32 gastrointestinal (37%), and 41 other (47%) bleedings according to ISTH guidelines and a total of 47 arterial (81%) and 11 venous (19%) cases of thrombo-embolism. Patients with heart valve dysfunction presented the highest TTR (76.0%), and still a significant increase in thrombo-embolic events (P ¼ 0.03) was seen compared with other indications of warfarin treatment ( Figure 5 ) showed a significant increase in the incidence of major bleedings with increasing age (P , 0.001). As expected, due to higher life expectancy in women, a significant age difference was seen between the sexes (P , 0.001). However, there was no statistical difference in risk of bleeding (P ¼ 0.46) or thrombosis (P ¼ 0.61) between the sexes.
Discussion
In patients on anticoagulation therapy, a strong correlation has been shown between high TTR and a reduction in complications such as bleeding and thrombosis. 4, 6 In a meta-analysis of 47 studies on anticoagulation therapy in atrial fibrillation, randomized trials were shown to be superior to retrospective studies (TTR 64.9 vs. 56.4%; P ¼ 0.01), and a high TTR correlated inversely to bleeding and thrombo-embolic complications. 4 In clinical practice, TTR usually has been lower, due to less selection bias, compared with organized trials. Differences in TTR have also been shown between anticoagulation clinics and community practice. A meta-analysis of eight studies with a total of 14 participating centres and 22 237 warfarin-treated patients in the USA presented a mean TTR of 55%, 5 where patients treated in anticoagulation clinics presented a mean TTR of 63% compared with 51% in Figure 4 Box plot of mean weekly dose of warfarin by 10-year age category; n ¼ 18 353, P , 0.001 for differences between age groups. The horizontal line indicates the median, the box covers the 25 -75% percentiles, and the maximum length of each whisker is 1.5 times the interquartile range. Points outside this range show up as outliers.
patients in community practice. In Sweden, however, these differences between anticoagulation clinics and community care were not present, 8 indicating different treatment regimens between countries. This, the first report from the Swedish national quality registry for anticoagulation and atrial fibrillation, AuriculA, shows that the quality of anticoagulation treatment given in the participating centres in Sweden is high. In this paper, we report a mean TTR of 76.2% in a large, unselected clinical population. If we expand the Figure 5 Events per patient-year by age categories in the whole AuriculA subgroup with 87 major bleedings according to ISTH definitions and 58 thrombo-embolic events. A significant correlation between age and major bleeding (P , 0.001) is seen, but no correlation between age and thrombo-embolic events (P ¼ 0.147).
. treatment range of INR to 1.8-3.2 for the coefficient of variation of the laboratory method of INR measurement as done in SPORTIF III, 13 the mean TTR is increased to 88.4% (data not shown). The foundation of organization of anticoagulation treatment in Sweden is built on anticoagulation centres, both in primary care and in hospital-based settings, and the number of doctors involved in dosage of warfarin outside these centres are very few in Sweden. Both large urban centres and small primary care centres from different parts of Sweden were represented in AuriculA, and although there may be differences in demographics between centres, especially between hospital-based centres and primary care centres, we believe that there is not a selection bias of patients in AuriculA. Since entire regions in Sweden enrol all their patients on anticoagulation treatment in AuriculA and all anticoagulation centres report data from every patient in that centre, we believe that the population is well representative of any other clinical population on anticoagulation treatment, at the very least in Sweden. In our study, the mean TTR in hospital-based centres was 75.7%, with respect to 80.3% TTR in primary care centres. A probable cause for this difference in TTR is that primary care centres treat a somewhat healthier population, where patients with multiple co-morbidities and medications, with subsequent difficulties of INR control are overrepresented in anticoagulation clinics. These data are consistent with earlier data 8 from Sweden, which, quite the opposite of American studies, 5 show that primary care centres can produce high-quality anticoagulation control.
In accordance with earlier data, 4 one would expect complications in AuriculA to be low, and our follow-up data from two centres in AuriculA (Malmö and Sundsvall) confirm this. In a subgroup of two centres in AuriculA, we identify a low risk of major bleeding and thrombo-embolic complication in patients on warfarin treatment at 2.6 and 1.7% per treatment year. In patients with atrial fibrillation, complications were 2.6 and 1.4%, respectively. These results are in line with, or in some cases even better compared with prospective randomized clinical trials of anticoagulation treatment with warfarin. 4, 6, 9, 13, 14 However, compared with randomized trials, the AuriculA population is representative of a clinical setting with older patients, and no exclusion criteria for treatment are present. Instead, it is up to each individual clinician to assess the risk -benefit for every single patient before referring them for anticoagulation treatment. The risk of bleeding was low for all treatment indications of warfarin, but we noticed a somewhat higher frequency of thrombo-embolic events at 2.7% per patient/treatment year in patients with heart valve dysfunction compared with 1.7% in the whole population. However, this is only one observation in a small number of patients, and we will do a follow-up on these data in future reports of AuriculA. Even though results were not significant, there was a trend towards lower (individual) TTR in patients with events compared with those without. As anticipated, patients with bleeding complications had an increased time .3.0 INR; P ¼ 0.001. In accordance with previous studies, 8, 15 our elderly AuriculA population was expected to have more major bleedings, compared with randomized controlled trials of warfarin treatment 6,9,13,14 in which patients were younger, and still the risk of major bleeding was very low. As expected, we found a correlation between age and major bleeding (Wilcoxon test; P , 0.001), but no correlation between age and thrombo-embolic events (Wilcoxon test; P ¼ 0.147) was seen. Age strongly correlates with the need of a lower warfarin dose to reach therapeutic INR in our study. This could be the result of less enzymatic activity in the liver, but the increased use of concurrent medication in the elderly, for example statins, probably affects the results. Although we do not have concurrent medications listed in our study, we hope that our data could assist physicians upon initiating warfarin therapy, aiming for lower doses in the elderly patients. Our data ( Figure 3 ) also indicate that elderly patients manage their warfarin therapy at least as well or even better than younger patients and that age itself should not affect the decision to start a patient on anticoagulation therapy, given no other contraindications are present. However, in spite of the high TTR values in the elderly, the increase in rates of major bleeding with increasing age still was significant ( Figure 5) . We are aware of the limitations in our study. The prevalence of cardiovascular death and death from any causes has not been studied and this, the first report from the national quality registry AuriculA, reports only data from the year 2008 and complications from two centres. Consequently, in some cases, patient numbers and treatment years were low. For example, patients with atrial fibrillation undergoing direct current (DC) cardioversion had the lowest TTR of all indications of warfarin treatment, but numbers were too low to evaluate the frequency of complications. The low TTR, presented in Table 1 , is probably due to the higher fraction of individuals recently started on warfarin in this group. Given a short duration of treatment in DC cardioversion patients, the fraction of INR values out of range during the treatment period is higher in this patient category than in patients with chronic anticoagulant treatment. We have had no possibility to investigate the CHADS 2 score in patients with atrial fibrillation, and no concomitant illnesses or medications have been listed. Subsequently, no evaluations, with the exception of gender and age, of risk factors for bleeding or thrombosis have been made. Therefore, no conclusion can be drawn from these data, and even though results are interesting, future reports of AuriculA will be needed to see whether these trends are reproducible, in which we hope data on the CHADS 2 score will be available.
However, as stated earlier, we believe that the AuriculA population is representative of a clinical setting, at least in Sweden, and that the TTR seen in this study reflects an organization that seems to be in good control of anticoagulation treatment with warfarin. Our data also support earlier data 4 that TTR is an excellent prognostic marker of the quality of anticoagulation treatment given in a clinical setting. Future reports of AuriculA will however be needed to see whether the trends reported in this study are reproducible. Awaiting the upcoming era of new oral anticoagulation therapy, our data give support for the need of an improved organization of specialized anticoagulation centres and treatment regimens in centres with low levels of TTR. The question whether anticoagulation therapy with warfarin in centres with high levels of TTR will be comparable to other oral anticoagulation treatments is however still to be answered. Central registries comparing complication frequencies between different oral anticoagulation treatments in a clinical setting will be needed to give further information of any differences in clinical benefits.
